TRCT
KAPA

Tower Research Capital (TRC)’s Kairos Pharma KAPA Stock Holding History

Tower Research Capital (TRC)’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43K Sell
3,733
-229
-6% -$119 ﹤0.01% 4825
2026
Q1 		$2.21K Sell
3,962
-265
-6% -$178 ﹤0.01% 4517
2025
Q4 		$3K Sell
4,227
-1,730
-29% -$1.62K ﹤0.01% 4438
2025
Q3 		$6.97K Buy
5,957
+2,160
+57% +$2.47K ﹤0.01% 4132
2025
Q2 		$2.69K Buy
+3,797
New +$2.76K ﹤0.01% 4608

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s KAPA Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Kairos Pharma (KAPA) stake by 5.8% in Q2 2026, selling an estimated $119 and leaving 3,733 shares worth $1.43K. The position accounts for ﹤0.01% of the portfolio, ranked #4825.

Tower Research Capital (TRC) first reported a position in KAPA in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.97K in Q3 2025. 9 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • Tower Research Capital (TRC) held 3,733 shares of Kairos Pharma worth $1.43K as of Q2 2026.
  • Tower Research Capital (TRC) sold 229 Kairos Pharma shares in Q2 2026, an estimated $119.
  • Kairos Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4825 holding.
  • Tower Research Capital (TRC) first reported a position in Kairos Pharma in Q2 2025 and has held it in 5 quarters since.
  • Tower Research Capital (TRC)'s Kairos Pharma position peaked at $6.97K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.